

SEMULOPARIN DATA AT ASCO 11 – Exploiting the gap through SAVE ONCO

<https://marketpublishers.com/r/S4011605E90EN.html>

Date: June 2011

Pages: 3

Price: US\$ 140.00 (Single User License)

ID: S4011605E90EN

Abstracts

Clinical data from the SAVE-ONCO study on semuloparin is positive, but the commercial potential depends on its relative benefits over existing anticoagulants in the market, which are currently extensively used, despite the indication not being on their label. The SAVE-ONCO study was the first of its kind in terms of the size and type of cancer patients that were recruited, but being placebo controlled, it is difficult to gauge, how it fares in comparison to the current standard of care (Lovenox /dalteparin). Lovenox/dalteparin/nadroparin have shown robust efficacy in terms of VTE prevention in cancer population in a number of clinical studies.

Contents

COMPANIES MENTIONED

SANOFI, SAN

I would like to order

Product name: SEMULOPARIN DATA AT ASCO 11 – Exploiting the gap through SAVE ONCO

Product link: <https://marketpublishers.com/r/S4011605E90EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S4011605E90EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970